These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20846739)

  • 41. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introduction of emerging medical devices on the market: a new procedure in Belgium.
    Vinck I; Neyt M; Thiry N; Louagie M; Ramaekers D
    Int J Technol Assess Health Care; 2007; 23(4):449-54. PubMed ID: 17937833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Introduction and uptake of new medical technologies in the Australian health care system: a qualitative study.
    Gallego G; Casey R; Norman R; Goodall S
    Health Policy; 2011 Oct; 102(2-3):152-8. PubMed ID: 21601934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health technology assessment, value-based decision making, and innovation.
    Henshall C; Schuller T;
    Int J Technol Assess Health Care; 2013 Oct; 29(4):353-9. PubMed ID: 23845404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Marketing approval and market surveillance of medical devices in Germany: Where does policy integration take place?].
    Lang A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(5-6):320-4. PubMed ID: 25066351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-approval studies in France, challenges facing medical devices.
    Levesque K; Coqueblin C; Guillot B; ; Aubourg L; Avouac B; Carbonneil C; Cucherat M; Descamps-Mandine P; Hanoka S; Goldberg M; Josseran A; Parquin F; Pitel S; Ratignier C; Sechoy O; Szwarcenstein K; Tanti A; Teiger E; Thevenet N
    Therapie; 2014; 69(4):303-21. PubMed ID: 25230354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Making innovations accessible to the poor through implementation research.
    Squire SB; Ramsay AR; van den Hof S; Millington KA; Langley I; Bello G; Kritski A; Detjen A; Thomson R; Cobelens F; Mann GH
    Int J Tuberc Lung Dis; 2011 Jul; 15(7):862-70. PubMed ID: 21682960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reconsidering Planning and Management of Medical Devices Procurement in Public Health Services in Cyprus.
    Theodorou M; Georgiou M; Nikolentzos A; Bellali T
    Glob J Health Sci; 2015 Apr; 7(6):205-14. PubMed ID: 26153175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring the role of ICT in the provision of integrated care--evidence from eight countries.
    Lluch M; Abadie F
    Health Policy; 2013 Jun; 111(1):1-13. PubMed ID: 23587547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methods for medical device and equipment procurement and prioritization within low- and middle-income countries: findings of a systematic literature review.
    Diaconu K; Chen YF; Cummins C; Jimenez Moyao G; Manaseki-Holland S; Lilford R
    Global Health; 2017 Aug; 13(1):59. PubMed ID: 28821280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions?
    Huff-Rousselle M
    Soc Sci Med; 2012 Nov; 75(9):1572-80. PubMed ID: 22835922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical technology in India: Tracing policy approaches.
    Chakravarthi I
    Indian J Public Health; 2013; 57(4):197-202. PubMed ID: 24351378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breaking up is hard to do: the economic impact of provisional funding contingent upon evidence development.
    Mortimer D; Li JJ; Watts J; Harris A
    Health Econ Policy Law; 2011 Oct; 6(4):509-27. PubMed ID: 21819632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Working to improve the management of sarcoma patients across Europe: a policy checklist.
    Kasper B; Lecointe-Artzner E; Wait S; Boldon S; Wilson R; Gronchi A; Valverde C; Eriksson M; Dumont S; Drove N; Kanli A; Wartenberg M
    BMC Cancer; 2018 Apr; 18(1):424. PubMed ID: 29661168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of medical diagnostics and medical devices in the East African community partner states.
    Rugera SP; McNerney R; Poon AK; Akimana G; Mariki RF; Kajumbula H; Kamau E; Mpawenimana S; Said SY; Toroitich A; Ronoh W; Sollis KA; Sonoiya S; Peeling RW
    BMC Health Serv Res; 2014 Oct; 14():524. PubMed ID: 25366990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical device procurement in low- and middle-income settings: protocol for a systematic review.
    Diaconu K; Chen YF; Manaseki-Holland S; Cummins C; Lilford R
    Syst Rev; 2014 Oct; 3():118. PubMed ID: 25336161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Designing for scale: development of the ReMotion Knee for global emerging markets.
    Hamner SR; Narayan VG; Donaldson KM
    Ann Biomed Eng; 2013 Sep; 41(9):1851-9. PubMed ID: 23525749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices.
    Husereau D; Henshall C; Jivraj J
    Int J Technol Assess Health Care; 2014 Jul; 30(3):241-9. PubMed ID: 24921416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.